WEP Group Holdings Limited (WEP Clinical) is pleased to announce the closure of an investment in the company made by The Jordan Company, L.P. (TJC), a middle-market private equity firm. Under the terms of [...]
WEP Clinical LTD (WEP), a specialist services company that works with drug developers to help patients and physicians gain early access to medicines when no other treatment options are available, has partnered with biopharmaceutical [...]
WEP Clinical Ltd (WEP), a specialist services company that works with drug developers to help patients and physicians gain early access to medicines, is pleased to announce the execution of a Master Services Agreement [...]
WEP Clinical today announced a partnership with Horizon Therapeutics plc to make a Named Patient Use (NPU) program available for TEPEZZA. The TEPEZZA NPU program is for patients with Thyroid Eye Disease (TED) in [...]
WEP Clinical (WEP) and Nabriva Therapeutics (Nabriva) are pleased to announce the expansion of the XENLETA® (lefamulin) Named Patient Program (NPP) into Australia, New Zealand, Singapore and South Africa. NPP is designed to ensure [...]
WEP Clinical (WEP) announced today that it has extended its partnership with BTG Specialty Pharmaceuticals (BTG), a division of Boston Scientific. Last year, WEP announced it would be partnering with BTG to supply the [...]
